Clinical Trial Update: Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy for cognitive deficits in adults with schizophrenia, sponsored by AbbVie; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Cognitive Deficits in Schizophrenia | Phase 2 | Status: COMPLETED